U.S., Aug. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07751250) titled 'Comparative PK Assessment Study of Casdatifan in Moderate Hepatically Impaired Participants Versus Matched Participants With Normal Hepatic Function' on Aug. 03.
Brief Summary: The purpose of the study is to compare the single dose PK of casdatifan between participants with moderate hepatic impairment (HI) and healthy matched control participants with normal hepatic function.
Study Start Date: Aug., 2026
Study Type: INTERVENTIONAL
Condition:
Healthy Participants
Hepatic Impairment
Intervention:
DRUG: Casdatifan
Participants will receive a 100 mg single oral dose of casdatifan.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: ...